Case Report of CCDC149–ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma
- 13 December 2022
- journal article
- case report
- Published by SAGE Publications in Thyroid®
- Vol. 32 (12) , 1580-1585
Abstract
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, usually with an indolent course. ALK fusions are rare in PTC but may give rise to a more aggressive behavior. We report a novel ALK fusion, CCDC149 – ALK , not previously described in PTC, detected by next-generation sequencing in a 30-year-old woman with progressive widely metastatic radioiodine-refractory (RAIR) disease to lung, muscle, and brain. The patient was started on alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor. Within eight weeks, her palpable disease had completely regressed, and the serum thyroglobulin decreased dramatically. Restaging imaging demonstrated an objective partial response. Our case highlights the role of ALK fusions in thyroid cancer and highlights its clinical significance in PTC. We recommend deep mutational sequencing in BRAF V600E -negative RAIR PTC to identify targetable genetic alterations, including gene fusions, that may result in dramatic therapeutic benefits.Keywords
This publication has 23 references indexed in Scilit:
- Characterization of thyroid cancer driven by known and novel ALK fusionsEndocrine-Related Cancer, 2019
- The Transcriptional Roles of ALK Fusion Proteins in TumorigenesisCancers, 2019
- Gene Fusions in Thyroid CancerThyroid®, 2018
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyThe Lancet, 2017
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung CancerCancer Discovery, 2016
- Biologic and Clinical Perspectives on Thyroid CancerNew England Journal of Medicine, 2016
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersJournal of Clinical Investigation, 2016
- A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid CarcinomaAmerican Journal of Surgical Pathology, 2015
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007